SeQuent Scientific to acquire 100% stake in Tineta Pharma
The acquisition is for an enterprise value of Rs. 218 crores
The acquisition is for an enterprise value of Rs. 218 crores
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The laboratory is equipped to perform high-volume diagnostic testing services
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
Subscribe To Our Newsletter & Stay Updated